Saumya Ramanayake1, Ian Bilmon2, David Bishop3, Ming-Celine Dubosq3, Emily Blyth2, Leighton Clancy4, David Gottlieb2, Kenneth Micklethwaite5. 1. The Westmead Millennium Institute for Medical Research, The University of Sydney, Westmead, Australia. 2. The Westmead Millennium Institute for Medical Research, The University of Sydney, Westmead, Australia; The Department of Haematology, Westmead Hospital, Westmead, Australia; Sydney Cellular Therapies Laboratory, Pathology West, Westmead, Australia. 3. The Westmead Millennium Institute for Medical Research, The University of Sydney, Westmead, Australia; The Department of Haematology, Westmead Hospital, Westmead, Australia. 4. The Westmead Millennium Institute for Medical Research, The University of Sydney, Westmead, Australia; Sydney Cellular Therapies Laboratory, Pathology West, Westmead, Australia. 5. The Westmead Millennium Institute for Medical Research, The University of Sydney, Westmead, Australia; The Department of Haematology, Westmead Hospital, Westmead, Australia; Sydney Cellular Therapies Laboratory, Pathology West, Westmead, Australia. Electronic address: kenneth.micklethwaite@sydney.edu.au.
Abstract
BACKGROUND AIMS: Protocols for the production of CD19-specific chimeric antigen receptor (CAR19) T cells are often complex and expensive because of the use of retroviral and lentiviral vectors or the need for CAR19 T-cell enrichment. We aimed to simplify the generation of CAR19 T cells from the peripheral blood of normal donors and patients using the piggyBac transposon system of gene modification. METHODS: We varied electroporation voltage, cytokines and stimulation conditions for the generation and expansion of CAR19 T cells over a 3-week culture period. RESULTS: Using optimized electroporation voltage, interleukin-15 alone and co-culturing CAR T cells with peripheral blood mononuclear cells, we were able to expand CAR19 T-cell cultures by up to 765-fold over 3 weeks in normal donors and 180-fold in patients with B-cell malignancies. Final median CAR19 expression of 72% was seen in normal donors, and 81% was seen in patients with acute lymphoblastic leukaemia, chronic lymphocytic leukemia or non-Hodgkin lymphoma. CAR19 T cells produced interferon gamma on stimulation with CD19(+) cell lines and efficiently lysed both CD19(+) cell lines and primary leukemia cells. In addition, combining CAR expression with an inducible caspase safety switch allowed elimination of CAR19 T cells by the application of a small molecule dimerizer. DISCUSSION: We have produced a simple, inexpensive and easily adoptable protocol for the generation of CAR19 T cells suitable for use in clinical trials using the piggyBac transposon system. This provides a robust platform for further enhancing the T-cell product and testing new CAR technologies.
BACKGROUND AIMS: Protocols for the production of CD19-specific chimeric antigen receptor (CAR19) T cells are often complex and expensive because of the use of retroviral and lentiviral vectors or the need for CAR19 T-cell enrichment. We aimed to simplify the generation of CAR19 T cells from the peripheral blood of normal donors and patients using the piggyBac transposon system of gene modification. METHODS: We varied electroporation voltage, cytokines and stimulation conditions for the generation and expansion of CAR19 T cells over a 3-week culture period. RESULTS: Using optimized electroporation voltage, interleukin-15 alone and co-culturing CAR T cells with peripheral blood mononuclear cells, we were able to expand CAR19 T-cell cultures by up to 765-fold over 3 weeks in normal donors and 180-fold in patients with B-cell malignancies. Final median CAR19 expression of 72% was seen in normal donors, and 81% was seen in patients with acute lymphoblastic leukaemia, chronic lymphocytic leukemia or non-Hodgkin lymphoma. CAR19 T cells produced interferon gamma on stimulation with CD19(+) cell lines and efficiently lysed both CD19(+) cell lines and primary leukemia cells. In addition, combining CAR expression with an inducible caspase safety switch allowed elimination of CAR19 T cells by the application of a small molecule dimerizer. DISCUSSION: We have produced a simple, inexpensive and easily adoptable protocol for the generation of CAR19 T cells suitable for use in clinical trials using the piggyBac transposon system. This provides a robust platform for further enhancing the T-cell product and testing new CAR technologies.
Authors: David C Bishop; Ning Xu; Benjamin Tse; Tracey A O'Brien; David J Gottlieb; Alla Dolnikov; Kenneth P Micklethwaite Journal: Mol Ther Date: 2018-06-01 Impact factor: 11.454
Authors: Lorenz Waldmeier; Ina Hellmann; Chantal K Gutknecht; Fabian I Wolter; Skylar C Cook; Sai T Reddy; Ulf Grawunder; Roger R Beerli Journal: MAbs Date: 2016-03-17 Impact factor: 5.857
Authors: Salvatore Fiorenza; David S Ritchie; Scott D Ramsey; Cameron J Turtle; Joshua A Roth Journal: Bone Marrow Transplant Date: 2020-05-30 Impact factor: 5.483
Authors: Ayesha Aijaz; Matthew Li; David Smith; Danika Khong; Courtney LeBlon; Owen S Fenton; Ronke M Olabisi; Steven Libutti; Jay Tischfield; Marcela V Maus; Robert Deans; Rita N Barcia; Daniel G Anderson; Jerome Ritz; Robert Preti; Biju Parekkadan Journal: Nat Biomed Eng Date: 2018-06-11 Impact factor: 25.671
Authors: Alex Moretti; Marianna Ponzo; Charles A Nicolette; Irina Y Tcherepanova; Andrea Biondi; Chiara F Magnani Journal: Front Immunol Date: 2022-06-09 Impact factor: 8.786
Authors: Kenneth P Micklethwaite; Kavitha Gowrishankar; Brian S Gloss; Ziduo Li; Janine A Street; Leili Moezzi; Melanie A Mach; Gaurav Sutrave; Leighton E Clancy; David C Bishop; Raymond H Y Louie; Curtis Cai; Jonathan Foox; Matthew MacKay; Fritz J Sedlazeck; Piers Blombery; Christopher E Mason; Fabio Luciani; David J Gottlieb; Emily Blyth Journal: Blood Date: 2021-10-21 Impact factor: 25.476